Xcout Intel
Attune Pharmaceuticals, Inc.
Attune Biotech Inc. is a biopharmaceutical company that develops novel medicines to treat underserved disorders, focusing on neuroimmune, inflammatory, infectious disease, and metabolic applications. The company utilizes a proprietary platform approach featuring its flagship candidate, Lodonal, which is engineered with pharmaceutical-grade consistency and precision dosing to restore immune balance.
Subscribe to see Attune Pharmaceuticals, Inc.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Attune Pharmaceuticals, Inc. at a glance
Attune Pharmaceuticals, Inc. is a biotechnology company headquartered in United States. Its most recent funding round, Series B, raised $23M in January 2019. Xcout tracks 3 named people at Attune Pharmaceuticals, Inc., including Dr. John Rosa (President and Interim Chief Medical Officer).
Attune Pharmaceuticals, Inc. leadership
- Dr. John RosaPresident and Interim Chief Medical Officer
- Glen FarmerChief Financial Officer
- Noreen GriffinFounder & CEO
Attune Pharmaceuticals, Inc. funding rounds
Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Series B | $23M | 7 named |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Investors
Attune Pharmaceuticals, Inc. competitors
A few of Attune Pharmaceuticals, Inc.'s closest competitors — see the full list of competitors and alternatives →
A clinical-stage biopharmaceutical company developing biotherapeutics for immune-mediated diseases using its ATTOBODY biologics platform. The company's lead candidate, ATTO-1310, targets interleukin-31 (IL-31), known as the 'itch cytokine,' for the treatment of chronic pruritic diseases including atopic dermatitis. Its pipeline also includes multi-specific candidates for other inflammatory diseases.
Adaptin Bio is a biotechnology company developing a proprietary drug delivery platform designed to enhance the transfer of therapeutics across biological barriers into the brain and other targeted tissues. Its lead technology, the Brain Bispecific T cell Engager (BRiTE) platform, manipulates the human immune system to target diseases in oncology, central nervous system disorders, autoimmune conditions, and cardiovascular markets.
Attralus, Inc. is a biopharmaceutical company headquartered in Naples, Florida, focused on creating transformative medicines and novel pan-amyloid removal therapeutics and diagnostics.
INmune Bio, Inc. is a clinical-stage biotechnology company focused on developing novel immunotherapies. Its primary objective is to harness the body's innate immune system to combat various illnesses. The company is actively engaged in developing and bringing to market therapeutic candidates designed to address a spectrum of conditions such as blood cancers, solid tumors, and chronic inflammatory diseases. Its pipeline features key development programs including: INKmune: Aimed at treating women suffering from relapsed or refractory ovarian carcinoma and individuals diagnosed with high-risk myelodysplastic syndrome. INB03: An immunotherapy targeting patients with both hematologic malignancies and solid tumors. XPro1595: Under development for the treatment of Alzheimer's disease. INmune Bio holds licensing agreements with entities including Xencor, Inc., Immune Ventures, LLC, the University of Pittsburgh, and University College London. Established in 2015, INmune Bio is headquartered in Boca Raton, Florida.
Autobahn Therapeutics is a biotechnology company headquartered in San Diego, California, focused on developing restorative treatments in the medical sector.
Autobahn Therapeutics, Inc. is a privately held biopharmaceutical company with its corporate office and headquarters located in San Diego, California, focused on restoring hope for patients.
Get Attune Pharmaceuticals, Inc.'s news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on Attune Pharmaceuticals, Inc. in Xcout Intel
- 3 named people with titles, LinkedIn and board committees
- 1 funding round with the investors in each, and who they co-invest with
- The full competitor set, tracking, exports and API access